Proximity-inducing drugs
“I don’t begrudge any industry scepticism,” adds Crews, who knows how long it took industry to take PROTACs seriously. “The onus is on us to demonstrate the utility of the creative fruits of our labours. We may not fully, at this point, appreciate what those opportunities are, but that shouldn’t stop us from being creative.”